Impact BioMedical, Inc. reported its financial results for the first quarter of 2026, revealing a total revenue of $7,000, a significant increase from zero revenue in the same period last year. This revenue primarily stems from the company's new product line, the Celios air purification technology, which was acquired in February 2025. Despite this revenue generation, the company incurred a net loss of $2.284 million, compared to a net loss of $1.278 million in the first quarter of 2025, marking a 79% increase in losses year-over-year.
The company's total expenses for the quarter rose to $2.296 million, a 127% increase from $1.010 million in the prior year. This increase was largely driven by a substantial rise in stock-based compensation, which amounted to $1.440 million, compared to just $2,000 in the previous year. Other notable changes included a 27% decrease in sales, general, and administrative compensation, and a 55% reduction in research and development expenses, reflecting the company's efforts to control costs amid ongoing financial challenges.
Impact BioMedical's balance sheet as of March 31, 2026, showed total assets of $17.086 million, a slight decrease from $17.405 million at the end of 2025. Current liabilities increased significantly to $1.687 million from $1.162 million, primarily due to an increase in amounts due to related parties, which rose to $1.103 million from $621,000. The company's stockholders' equity also declined to $11.464 million from $12.311 million, reflecting the ongoing losses and the impact of stock-based compensation.
In terms of operational developments, the company continues to explore strategic partnerships and potential acquisitions to enhance its product offerings and market presence. The management is focused on monetizing its intellectual properties and controlling operating costs to improve liquidity. The company is also actively seeking to expand its geographic reach and product adoption rates, particularly in the biopharmaceutical and wellness sectors.
Looking ahead, Impact BioMedical acknowledges the substantial doubt regarding its ability to continue as a going concern, given its history of operating losses and negative cash flows. The management is exploring various options to raise capital, including potential listings on the NYSE American and debt financing. However, there is no certainty that these plans will be successful, and the company remains committed to taking necessary actions to ensure its sustainability in the competitive healthcare market.
About IMPACT BIOMEDICAL INC.
Impact BioMedical Inc. is a biotech company focused on discovering, developing, and licensing innovative technologies for human healthcare and wellness. Its core activities include biopharmaceuticals, consumer wellness products, and drug discovery targeting neurological, oncologic, and inflammatory diseases. The company leverages proprietary science, strategic partnerships, and intellectual property to commercialize solutions through licensing and direct sales, addressing unmet medical needs globally.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.